Read by QxMD icon Read

Bladder cancer, biomarkers

Rita Azevedo, Janine Soares, Cristiana Gaiteiro, Andreia Peixoto, Luís Lima, Dylan Ferreira, Marta Relvas-Santos, Elisabete Fernandes, Ana Tavares, Sofia Cotton, Ana Luísa Daniel-da-Silva, Lúcio Lara Santos, Rui Vitorino, Francisco Amado, José Alexandre Ferreira
Bladder Cancer (BC) presents one of the highest recurrence rates amongst solid tumours and constitutes the second deadliest disease of the genitourinary track. Non-invasive identification of patients facing disease recurrence and/or progression remains one of the most critical and challenging aspects in disease management. To contribute to this goal, we demonstrate the potential of glycan-affinity glycoproteomics nanoplatforms for urinary biomarkers discovery in bladder cancer. Briefly, magnetic nanoprobes (MNP) coated with three broad-spectrum lectins, namely Concanavalin A (ConA; MNP@ConA), Wheat Germ Agglutinin (WGA; MNP@WGA), and Sambucus nigra (SNA; MNP@SNA), were used to selectively capture glycoproteins from the urine of low-grade and high-grade non-muscle invasive as well as muscle-invasive BC patients...
July 1, 2018: Talanta
Taku Naiki, Aya Naiki-Ito, Keitaro Iida, Toshiki Etani, Hiroyuki Kato, Shugo Suzuki, Yoriko Yamashita, Noriyasu Kawai, Takahiro Yasui, Satoru Takahashi
Herein, we elucidated the molecular mechanisms and therapeutic potential of glutathione peroxidase 2 (GPX2) in bladder cancer. GPX2 expression gradually increased during progression from normal to papillary or nodular hyperplasia (PNHP) and urothelial carcinoma (UC) in a rat N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced bladder carcinogenesis model. GPX2 overexpression was more marked in UC with squamous differentiation (SqD) than in pure UC. Clinical intraepithelial lesions of papillary UC and invasive UC with SqD also had strong GPX2 expression in human radical cystectomy specimens...
March 23, 2018: Oncotarget
Jin-Shan Wang, Qing-Hong Liu, Xiao-Hua Cheng, Wen-Yuan Zhang, Yong-Chao Jin
The incidence and mortality rate of bladder cancer have dramatically expanded, so it's urgent to discover new biomarker and therapeutic target for bladder cancer. Recently, lncRNA has been identified as oncogene or tumor suppressor to regulate the tumorigenesis. LncRNA ZFAS1 has been confirmed as oncogene in various tumors. However, the expression, function, and underlying mechanism of ZFAS1 in bladder carcinogenesis have yet to be totally clarified. In the current study, our data demonstrated that ZFAS1 expression was significantly upregulated in bladder cancer tissues and cell lines...
April 10, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Wei Shen Tan, Wei Phin Tan
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
Zheng Tan, Ninadh M D'Costa, Peter A Raven, Claudia Chavez-Munoz, Alan I So
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
Ryan W Dobbs, Michael R Abern
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
Zhiyong Tuo, Jianbin Zhang, Wei Xue
Long noncoding RNAs (lncRNAs) have been identified to have more and more important roles in tumorigenesis and may be novel biomarker for cancer therapy. LncRNA TP73-AS1 is a novel identified lncRNA that has been demonstrated to be increased in several cancers, however, its function in bladder cancer remains unknown. The aim of this work was to examine the expression and role of lncRNA TP73-AS1 in bladder cancer. The expression levels of lncRNA TP73-AS1 in bladder cancer tissues and cell lines were determined by quantitative real-time PCR (qRT-PCR), and its clinical significance was assessed by statistical analysis...
April 3, 2018: Biochemical and Biophysical Research Communications
Jun Xiao, Sanqiang Niu, Jiahong Zhu, Lei Lv, Hui Deng, Daqing Pan, Deyun Shen, Congyun Xu, Zhou Shen, Tao Tao
With the discovery of new chemotherapeutic drugs, chemotherapy becomes increasingly valuable. However, the resistance of tumor cells to chemotherapeutic agents significantly limits the effectiveness and causes chemotherapy failure. MicroRNAs have been shown to regulate drug resistance in many types of cancer. In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita‑Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H‑bc) and conducted a multi‑group test...
April 4, 2018: Oncology Reports
Simon Crabb, Sarah J Danson, James W F Catto, Cathy McDowell, James N Lowder, Joshua Caddy, Denise Dunkley, Jessica Rajaram, Deborah Ellis, Stephanie Hill, David Hathorn, Amy Whitehead, Mihalis Kalevras, Robert Huddart, Gareth Griffiths
BACKGROUND: Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, , Cancer Research UK, Accessed 26 Mar 2018). Cisplatin-based chemotherapy is standard of care therapy for UBC for both palliative first-line treatment of advanced/metastatic disease and radical neoadjuvant treatment of localised muscle invasive bladder cancer...
April 3, 2018: Trials
Kentaro Inamura
Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have been few advances in its clinical management due to a poor understanding of the correlations between its molecular and clinical features. Mounting evidence suggests that bladder cancer comprises a group of molecularly heterogeneous diseases that undergo a variety of clinical courses and possess diverse therapeutic responses. Owing to the close association between its molecular subtypes and clinicopathological features, specific therapeutic strategies have recently been suggested...
April 1, 2018: Cancers
Zhenzhen Liang, Rui Xin, Yinghui Yu, Rui Wang, Chunpeng Wang, Xin Liu
OBJECTIVE: This study is a meta-analysis and aims to determine the value of urinary survivin for detecting bladder cancer (BC) on the basis of preceding statistical performance and to compare their diagnostic value. MATERIALS AND METHODS: Considering that the urinary survivin data were from both RNA and protein levels, the key words "bladder cancer" AND "survivin" and "bladder cancer" AND "survivin RNA" were used; and PubMed, Web of Science, and Cochrane Library were systematically searched to identify relevant articles...
April 2, 2018: World Journal of Urology
Qiaqia Li, Chao Li, Jinbo Chen, Peihua Liu, Yu Cui, Xinyi Zhou, Huihuang Li, Xiongbing Zu
PURPOSE: To explore the function of NORAD in bladder cancer (BC), and to verify whether NORAD could be used as a biomarker to determine preoperative presence of progression and lymph node metastasis. To our knowledge, it is the first study investigating NORAD and its implications in BC. METHODS: BC specimens of 90 patients underwent bladder cystectomy or transurethral resection between January 2012 to December 2016 were tested by fluorescence in situ hybridization...
March 28, 2018: Urologic Oncology
Yair Lotan, Solomon L Woldu, Oner Sanli, Peter Black, Matthew I Milowsky
OBJECTIVES: To model the cost-effectiveness (CE) of a biomarker-based approach to select patients for neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: We obtained most recently clinical studies on locally-advanced bladder cancer treated by RC, including stage distributions, overall survival (OS) estimates, associated costs, and utilization/response to NAC. Additionally, we estimated the putative efficacy of 3 biomarkers to select patients for NAC: DNA repair gene panel [ATM, RB1, and FANCC], ERCC2, and RNA subtypes...
March 31, 2018: BJU International
Jie Lian, Shu-Hong Lin, Yuanqing Ye, David W Chang, Maosheng Huang, Colin P Dinney, Xifeng Wu
MicroRNAs (miRNAs) are implicated in the development of nearly all cancers and may function as promising biomarkers for early detection, diagnosis and prognosis. We sought to investigate the role of serum miRNAs as potential diagnostic biomarkers or biomarkers of risk for early-stage bladder cancer. First, we profiled global serum miRNAs in a pilot set of 10 non-muscle invasive bladder cancer (NMIBC) cases and 10 healthy controls matched on age, gender and smoking status. Eighty nine stably detectable miRNAs were selected for further testing and quantification by high-throughput Taqman analysis using the Fluidigm BioMark HD System to assess their association with NMIBC risk in both discovery and validation sets totaling 280 cases and 278 controls...
March 13, 2018: Oncotarget
Cristina Vallone, Giuliano Rigon, Caterina Gulia, Alberto Baffa, Raffaella Votino, Giulia Morosetti, Simona Zaami, Vito Briganti, Francesco Catania, Marco Gaffi, Roberto Nucciotti, Fabio Massimo Costantini, Roberto Piergentili, Lorenza Putignani, Fabrizio Signore
Non-coding RNAs (ncRNAs) are involved in the regulation of cell metabolism and neoplastic transformation. Recent studies have tried to clarify the significance of these information carriers in the genesis and progression of various cancers and their use as biomarkers for the disease; possible targets for the inhibition of growth and invasion by the neoplastic cells have been suggested. The significance of ncRNAs in lung cancer, bladder cancer, kidney cancer, and melanoma has been amply investigated with important results...
March 29, 2018: Genes
Zhong Li, Yuanjie Niu
BACKGROUND: The Long non-coding RNA (lncRNA) H19 is involved in carcinogenesis, progression, and metastasis. However, the association between genetic variants in H19 and bladder cancer susceptibility has not been reported. This case-control study assessed the association between H19 genetic variants and susceptibility to bladder cancer in a Chinese Han population. METHODS: In this study, 200 patients with bladder cancer and 200 healthy controls were surveyed and compared for frequencies of the genotypes of the H19 gene...
March 28, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
Iwona Belczacka, Agnieszka Latosinska, Justyna Siwy, Jochen Metzger, Axel S Merseburger, Harald Mischak, Antonia Vlahou, Maria Frantzi, Vera Jankowski
Urinary profiling datasets, previously acquired by capillary electrophoresis coupled to mass-spectrometry were investigated to identify a general urinary marker pattern for detection of solid tumors by targeting common systemic events associated with tumor-related inflammation. A total of 2,055 urinary profiles were analyzed, derived from a) a cancer group of patients (n = 969) with bladder, prostate, and pancreatic cancers, renal cell carcinoma, and cholangiocarcinoma and b) a control group of patients with benign diseases (n = 556), inflammatory diseases (n = 199) and healthy individuals (n = 331)...
March 27, 2018: Scientific Reports
Atif Ali Hashmi, Zubaida Fida Hussain, Muhammad Irfan, Muhammad Muzzammil Edhi, Sarah Kanwal, Naveen Faridi, Amir Khan
OBJECTIVES: Well differentiated keratinized squamous component as a part of urothelial carcinoma can be easily appreciated; however non-keratinizing squamous differentiation closely resembles urothelial differentiation. In addition prognostic significance of CK 5/6 expression in the absence of apparent squamous differentiation is still unclear. Therefore, in the present study we aimed to evaluate the frequency of CK 5/6 expression in 127 cases of urothelial carcinoma and its prognostic significance in loco-regional population...
March 27, 2018: BMC Research Notes
Eva Compérat, Caroline Eymerit, Julien Moroch, Justin Varinot
In recent years, fundamental research has yielded new insights into tumour biology, and new treatments have been developed. This review highlights the role of the pathologist and how he can support clinicians to find the right treatment for each patient. We explain the problems of the molecular subgroups of bladder cancer, the role of neo-adjuvant chemotherapy in the context of these findings, and show the important role of checkpoint inhibitors. Furthermore we focus on kidney cancer, with the clear cell carcinoma as the most frequent tumour type...
April 2018: Aktuelle Urologie
Arabinda Das, Anirban Biswas, Debendra Nath Guha Mazumder
Skin lesion is one of the important health hazards caused by high intake of arsenic through drinking water and diet, and the other hazards include several types of cancers (viz. skin, lung and urinary bladder), ischemic heart disease, hypertension, etc. Two most important biomarkers to measure arsenic intake in a human body are arsenic concentration in urine and hair. The primary interest of this paper is the association between skin lesion and arsenic concentration in hair for participants with chronic arsenic exposure from West Bengal, India, using bivariate regression model based on copula function...
March 26, 2018: Environmental Geochemistry and Health
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"